Skip to main content

CORRECTION article

Front. Pharmacol., 21 November 2022
Sec. Integrative and Regenerative Pharmacology
Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.1073510

Corrigendum: Pharmacological activity and clinical use of PDRN

This article is a correction to:

  1. Pharmacological Activity and Clinical Use of PDRN

    1. Read original article
Francesco Squadrito Francesco Squadrito1*Alessandra BittoAlessandra Bitto1Natasha IrreraNatasha Irrera1Gabriele PizzinoGabriele Pizzino1Giovanni PallioGiovanni Pallio1Letteria MinutoliLetteria Minutoli1Domenica AltavillaDomenica Altavilla2
  • 1Section of Pharmacology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
  • 2Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy

A Corrigendum on
Pharmacological activity and clinical use of PDRN

by Squadrito F, Bitto A, Irrera N, Pizzino G, Pallio G, Minutoli L and Altavilla D (2017). Front. Pharmacol. 8:224. doi: 10.3389/fphar.2017.00224

In the published article, the Conflict of Interest statement was incorrectly filed. Disclaimers on patents were omitted from the article. The correct Conflict of Interest statement appears below.

“Author FS has received research support from Mastelli for work on polydeoxyribonucleotide. Authors FS, AB, and DA are co-inventors on a patent describing therapeutic polydeoxyribonucleotide activity in chronic intestinal disease. Author LM is a co-inventor on a patent describing therapeutic polydeoxyribonucleotide activity in testicular injury by torsion.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: adenosine A2 receptors, DNA, oligonucleotides, PDRN, wound healing

Citation: Squadrito F, Bitto A, Irrera N, Pizzino G, Pallio G, Minutoli L and Altavilla D (2022) Corrigendum: Pharmacological activity and clinical use of PDRN. Front. Pharmacol. 13:1073510. doi: 10.3389/fphar.2022.1073510

Received: 18 October 2022; Accepted: 19 October 2022;
Published: 21 November 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Squadrito, Bitto, Irrera, Pizzino, Pallio, Minutoli and Altavilla. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Francesco Squadrito, francesco.squadrito@unime.it

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.